Research Evidence Anecdotal Efficacy Side Effects Price Dosing & Protocol Regulatory Safety Notes

Hexarelin

Hexarelin is a synthetic six‑amino‑acid growth‑hormone‑releasing peptide that is taken off‑label primarily for muscle growth and fat loss. In the community the modal dose is 200 µg per day, with timing and cycling rarely specified, while clinician‑guided protocols typically use 2 µg daily administered subcutaneously. The main limitation is that the off‑label evidence base is thin, with few published results and no FDA‑approved indication; injection‑site reactions have not emerged as a consistent theme.

Half-life~1.1 h

Data last updated July 22, 2026

Measured on 5 of 6 axes

Research Evidence

Evidence shape

Hexarelin occupies a low evidence tier, with its human literature limited to four small-scale diagnostic and mechanistic studies. While these publications explore its physiological effects, the peptide lacks any registered clinical trials or large-scale human data to support therapeutic use. The current research landscape remains confined to these exploratory human findings and preclinical animal models, leaving the peptide without the rigorous, multi-trial validation required to establish clinical efficacy or safety profiles for broader applications.

Depthhow much

0 registered trials

Breadthhow many areas

2 indications mapped

1 thin / exploratory · 1 animal-only

Qualityhow rigorous

No completed trials

Breadth and depth23 rows captured

Human

direct clinical signal

4

Animal

translational support

12

In vitro

mechanistic support

7

HighMediumLow

Source data

Every row behind the score.

23 total

CrosPMID 10342360n=7

Diagnostic & mechanistic studies

tested left ventricular ejection fraction (LVEF), mean blood pressure, heart rate, GH, aldosterone, catecholamines, cortisol

result HEX increased LVEF (70.7±3.0 vs 64.0±1.5%, p<0.03), peaking at 30 min, lasting ~60 min; MBP and HR unchanged; GH AUC matched rhGH. Effect deemed GH-independent.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

HumaPMID 1400881n=5

Diagnostic & mechanistic studies

tested GH AUC (µg/L·2h) over 2h post-bolus by RIA

result GHRP 1 µg/kg iv bolus maintained GH release during GHRH-induced pituitary desensitization; GHRH bolus GH response was abolished under the same conditions. GH axis independence of endogenous GHRH confirmed.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

HumaPMID 15305235n=12

Diagnostic & mechanistic studies

tested GH AUC (μg/l × 120 min) in response to Hex, GHRH, and exercise after prior GHRH+Hex maximal stimulation

result GHRH+Hex AUC ~2× higher in young vs old (11,260 vs 5,366). Hex response preserved in both groups (young 919, old 1,077); EX and GHRH responses abolished in older males.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CrosPMID 9156035n=8

Diagnostic & mechanistic studies

tested Peak GH and AUC GH response during morning wakefulness vs nocturnal sleep

result Morning peak GH 58.2±4.7 µg/L vs sleep 61.2±4.3 µg/L (NS); AUC sleep 1466±145 vs morning 903±94 µg·min/L (P<0.001); GH t½ longer during sleep (64.9 vs 24.9 min, P<0.01).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

AnimalPMID 17766487